

South Dakota Department of Social Services, Division of Medicaid Services Pharmacy & Therapeutics (P&T) Committee Meeting Minutes

Friday, June 15, 2018

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	X	Kelley Oehlke, PharmD	X
Dana Darger, RPh		Lenny Petrik, PharmD	X
James Engelbrecht, MD	X	Timothy Soundy, MD	
Mikal Holland, MD		Mike Jockheck, DSS Staff	X
Richard Holm, MD	X	Sarah Akers, DSS Staff	X
Bill Ladwig, RPh, Chair	X	Mary Carpenter, MD, DSS Staff	X

Administrative Business

The meeting was called to order by Ladwig at 1:05 PM. The minutes of the March meeting were presented. Baack made a motion to approve. Oehlke seconded the motion. Motion was approved unanimously.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report for January 1, 2018 through March 31, 2018. There were a total of 1,236 PAs reviewed during this time period. There were 275 requests (22%) received via telephone and 961 requests (73%) received via fax. PA appeals information were also reviewed.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from January 1, 2018 to March 31, 2017. The top five classes were atypical antipsychotics, insulins, respiratory and CNS stimulants, amphetamines, and anticonvulsants. The top 15 therapeutic classes make up 28.39% of total claims. The committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 13.26% of total claims. Neuraminidase inhibitors moved to the top 15 therapeutic classes by total cost of claims during this quarter.

Review of PA Forms & Criteria

The committee reviewed requested utilization and PA statistics for an in-depth review of specific PA criteria identified at the previous meeting. The following PA criteria were targeted for an update or selected for deeper review for the next meeting.

- Non-Sedating Antihistamines – PA on levocetirizine 5 mg tab will be removed
- Nasal Steroids – Committee requested in-depth utilization data on mometasone 50 mcg spray
- Proton Pump Inhibitors – Committee requested in-depth utilization data such as patients' age on all packs/chews/liquids

Review of Lyrica PA

Committee requested utilization data for Lyrica.

Review criteria for Genitourinary Smooth Muscle Relaxants PA

Committee reviewed criteria and commented changes were not necessary.

Review of PCSK9 Inhibitors

Committee requested utilization data for PCSK9 inhibitors.

Review of Duzallo & Zurampic

The committee reviewed clinical information on Duzallo and Zurampic and utilization summary of all anti-gout agents. After review and consideration, Committee commented PA was not necessary at this time. Committee will monitor this class.

Review of Ingrezza

The committee reviewed clinical information on Ingrezza and utilization summary of all agents used to treat tardive dyskinesia. After review and consideration, Committee commented PA was not necessary at this time. Committee will monitor this class.

Opioids antitussives for children

Committee reviewed the proposed PA criteria for opioid antitussives for recipients under 18 years old. Committee requested to review it again at the September meeting. Committee requested information on how other State Medicaid programs are covering the opioid antitussives for children.

Review of Aimovig

Committee requested to review it again at the September meeting and review proposed PA criteria for the CGRP antagonist class.

The September meeting is scheduled for 9/7/2018. Baack made a motion to adjourn. Oehlke seconded the motion. The meeting adjourned at 2:35 PM.